aczone
(dapsone)Allergan, Inc.
Usage: ACZONE® Gel, 5%, is indicated for the topical treatment of acne vulgaris.
61 results
aczone
(dapsone)Almirall, LLCUsage: ACZONE® (dapsone) Gel, 7.5%, is indicated for the topical treatment of acne vulgaris in patients aged 9 years and older.adapalene
(ADAPALENE)Alembic Pharmaceuticals Inc.Usage: Adapalene gel, 0.3%, is indicated for the topical treatment of acne vulgaris in patients aged 12 and older.aklief
(trifarotene)Galderma Laboratories, L.P.Usage: AKLIEF Cream is a retinoid indicated for the topical treatment of acne vulgaris in patients aged 9 years and older.altreno
(tretinoin)Bausch Health US, LLCUsage: ALTRENO® (tretinoin) lotion, 0.05% is indicated for the topical treatment of acne vulgaris in patients aged 9 years and older.arazlo
(tazarotene)Bausch Health US, LLCUsage: ARAZLO® (tazarotene) lotion, 0.045% is indicated for the topical treatment of acne vulgaris in patients aged 9 and older.claravis
(Isotretinoin)Teva Pharmaceuticals USA, Inc.Usage: Claravis (isotretinoin capsules) is indicated for the treatment of severe recalcitrant nodular acne in patients unresponsive to conventional therapies. It is reserved for non-pregnant patients due to risks of severe birth defects and may result in prolonged remission after a single 15-20 week course.cleocin t
(clindamycin phosphate)Pharmacia & Upjohn Company LLCUsage: CLEOCIN T Topical Solution, Gel, and Lotion are indicated for the treatment of acne vulgaris. Physicians should weigh the potential risks of diarrhea, bloody diarrhea, and pseudomembranous colitis when considering this medication.clindacin p
(clindamycin phosphate)Medimetriks Pharmaceuticals, Inc.Usage: Clindacin•P® is indicated for the treatment of acne vulgaris. Physicians should consider the risk of diarrhea and colitis when prescribing and evaluate the appropriateness of other treatments.clindagel
(CLINDAMYCIN)Bausch Health US, LLCUsage: CLINDAGEL (clindamycin phosphate topical gel, 1%) is indicated for the treatment of mild to moderate acne vulgaris. Clinical studies demonstrate its effectiveness in reducing inflammatory and non-inflammatory lesions compared to a vehicle gel, with a notable reduction in total lesion counts over a 12-week period.